A few days ago, the first "Orange Island Forum on Early Diagnosis and Treatment of Liver Cancer" hosted by the University of South China was held in Changsha, and more than 200 experts and scholars from universities and hospitals across the country participated in the forum.
Gao Shan, Secretary of the Party Committee of the University of South China, looks forward to taking the forum as an opportunity to promote the research and clinical application of early diagnosis and treatment of liver cancer to a new level, and make greater contributions to protecting people's lives and health.
Lu Xiulan, deputy director of the Medical Administration Department of the Hunan Provincial Health Commission, highly affirmed the achievements of the University of South China in medical education and research collaboration, scientific and technological innovation, etc., and said that she would continue to support the breakthrough of medical science and technology innovation and the development of discipline construction, and believed that the Hunan Provincial Engineering Research Center for early diagnosis and early treatment of liver cancer and the medical education of the University of South China will achieve greater success in the future.
Nan Yuemin, chairman-elect of the Hepatology Branch of the Chinese Medical Association, hopes to promote the application of new technologies and methods for early screening of liver cancer through forum exchanges, which will greatly improve the clinical level, benefit more patients, and contribute to the construction of a healthy China.
At the opening ceremony of the forum, Professor Cao Deliang, director and chief scientist of Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, made a theme report on "Introduction of Engineering Research Center and Achievement Transformation Exhibition", introducing a series of achievements and main work plans made by the center in the innovative research and development and clinical transformation and application of liver cancer screening, diagnosis and treatment products since its establishment.
After the opening ceremony, Professor Nan Yuemin, Professor Zhang Quan, Vice Chairman of the Hepatology Branch of Guizhou Medical Association and Director of the Department of Infectious Diseases of the Affiliated Hospital of Guizhou Medical University, Professor Shen Feng, Chairman of the Liver Cancer Expert Committee of the Chinese Society of Clinical Oncology and Dean of the Clinical Research Institute of the Oriental Hepatobiliary Surgery Hospital, Professor Peng Chuang, Chairman of the Hepatobiliary Surgery Society of the Hunan Medical Association and Executive Vice President of the Hepatobiliary Hospital of Hunan Provincial People's Hospital, Professor Du Shunda, director of the Department of Liver Surgery in Beijing, gave keynote reports on the topics of "Advances in Early Screening and Early Diagnosis of Liver Cancer", "Interpretation of Secondary Prevention of Primary Liver Cancer", "Individualized Surgery for Hepatobiliary Tumors", "Exploration and Practice of Laparoscopic Liver S7 Resection", and "Application Value of AKR1B10 in the Diagnosis and Treatment of Liver Cancer". Experts and scholars at the meeting conducted in-depth exchanges and discussions on the prevention, diagnosis and development of liver cancer. They highly praised Professor Cao Deliang's original discovery of a new liver cancer marker and the successful development of AKR1B10 new liver cancer diagnostic reagent that is superior to existing similar clinical products, and highly praised its clinical performance, and looked forward to a wider range of clinical applications.
It is reported that liver cancer ranks fifth in the incidence of cancer and second in death in China, mainly because of the large population base and low early diagnosis rate in China. In order to promote the implementation and achieve the requirements of the "Healthy China 2030" Planning Outline, the goal of increasing the 5-year survival rate of liver cancer by 15%, and improving the level of early screening of liver cancer is one of the main tasks. After more than 10 years of in-depth research, Cao Deliang's scientific research team has successfully developed a new type of primary liver cancer diagnostic reagent, AKR1B10 new liver cancer diagnostic reagent, which has proved its high sensitivity and high specificity in the early diagnosis of liver cancer, especially in early diagnosis, which is very convenient for liver cancer screening, diagnosis and disease monitoring, and effectively avoids ineffective and excessive.
This forum was organized by Hunan Provincial Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer and Hengyang Medical College, and co-organized by Hunan Laituofu Biotechnology.
Correspondent Zeng Xi, Xiaoxiang Morning News reporter Li Nan, intern Lei Zhijing.
Breaking news and rights protection channel: the application market **"Chen**" client, search for "help" and go directly to the "Chenyi Help" platform with one click; Or call **0731-85571188. Special 19176699651 for government and enterprise content services.